PT717638E - Ciclodextrinas para a reducao da toxicidade por extravasao provocada por substancias citotoxicas - Google Patents

Ciclodextrinas para a reducao da toxicidade por extravasao provocada por substancias citotoxicas

Info

Publication number
PT717638E
PT717638E PT94927983T PT94927983T PT717638E PT 717638 E PT717638 E PT 717638E PT 94927983 T PT94927983 T PT 94927983T PT 94927983 T PT94927983 T PT 94927983T PT 717638 E PT717638 E PT 717638E
Authority
PT
Portugal
Prior art keywords
compositions
cytotoxic
cyclodextrin
ulceration
compound
Prior art date
Application number
PT94927983T
Other languages
English (en)
Inventor
Joseph Rubinfeld
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of PT717638E publication Critical patent/PT717638E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT94927983T 1993-09-03 1994-09-02 Ciclodextrinas para a reducao da toxicidade por extravasao provocada por substancias citotoxicas PT717638E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11672493A 1993-09-03 1993-09-03
US08/297,249 US5602112A (en) 1992-06-19 1994-08-26 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
PT717638E true PT717638E (pt) 2002-07-31

Family

ID=26814548

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94927983T PT717638E (pt) 1993-09-03 1994-09-02 Ciclodextrinas para a reducao da toxicidade por extravasao provocada por substancias citotoxicas

Country Status (13)

Country Link
US (6) US5602112A (pt)
EP (1) EP0717638B1 (pt)
JP (1) JPH09502185A (pt)
AT (1) ATE214290T1 (pt)
AU (1) AU7718694A (pt)
CA (1) CA2172159C (pt)
DE (1) DE69430126T2 (pt)
DK (1) DK0717638T3 (pt)
ES (1) ES2171462T3 (pt)
HU (1) HUT73778A (pt)
IL (1) IL110825A0 (pt)
PT (1) PT717638E (pt)
WO (1) WO1995006485A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
WO1994022445A2 (en) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
DK0914102T3 (da) 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
HUP9701945A3 (en) * 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GB9921958D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
AU2001259298A1 (en) * 2000-05-02 2001-11-12 Advanced Medicine, Inc. Polyacid glycopeptide derivatives
SI1278549T1 (sl) 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
US6872804B2 (en) * 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
WO2001098327A2 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
IT1318689B1 (it) * 2000-09-12 2003-08-27 Pharmacia & Upjohn Spa Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
US6528076B2 (en) 2001-07-06 2003-03-04 Magic Herb Corp. Topical compositions and methods for treating pain
GB0127677D0 (en) * 2001-11-19 2002-01-09 Vianex S A Inclusion complex
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US6828311B2 (en) 2002-05-29 2004-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulation for the parenteral application of a sodium channel blocker
NZ538584A (en) * 2002-09-05 2007-05-31 Bharat Serums & Vaccines Ltd Stable liquid composition of oxazaphosphorine, mesna and etherified beta-cyclodextrin
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
JP5021318B2 (ja) * 2004-01-30 2012-09-05 ファイザー・プロダクツ・インク β−シクロデキストリンを液体投薬形態に用いて多用量製剤を達成するための抗菌性防腐剤
JP5225092B2 (ja) * 2005-10-14 2013-07-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チピファルニブの新規ｉｖ調合物
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CN100486645C (zh) 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
AU2007325576B2 (en) 2006-10-20 2013-01-10 Icos Corporation Compositions of Chk1 inhibitors
US20100021400A1 (en) * 2008-04-25 2010-01-28 Rhode Island Hospital Active Sunscreen Composition
EP2400987B1 (en) * 2009-02-25 2014-09-03 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
CN102458114A (zh) 2009-05-29 2012-05-16 锡德克斯药物公司 包含环糊精衍生物的可注射美法仑组合物及其制备和使用方法
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) * 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
MX346432B (es) * 2011-09-18 2017-03-21 Euro-Celtique S A * Composiciones farmaceuticas.
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP3027212A1 (en) * 2013-08-02 2016-06-08 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
US9919002B2 (en) 2013-10-21 2018-03-20 North Carolina State University Methods and constructs for compound delivery
RU2587716C2 (ru) * 2014-01-14 2016-06-20 Борис Игоревич Круглый Стабильный фармацевтический состав на основе актиномицина д для инъекций
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735189B2 (pt) * 1972-01-06 1982-07-27
US4024223A (en) * 1972-11-11 1977-05-17 Teijin Limited Stripe composition and method of reducing smell associated therewith
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS54115368A (en) * 1978-03-01 1979-09-07 Ono Pharmaceut Co Ltd Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent
IT1113341B (it) * 1978-03-31 1986-01-20 Ono Pharmaceutical Co Analoghi della 6,9-metano-pgi2
US4352793A (en) * 1979-04-26 1982-10-05 Sumitomo Chemical Company, Limited Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin
JPS6033430B2 (ja) * 1980-05-12 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
AU558787B2 (en) * 1981-01-23 1987-02-12 Wellcome Foundation Limited, The Inclusion complexes of cyclodextrins and cardiac clycosides
US4407795A (en) * 1981-07-16 1983-10-04 American Cyanamid Company Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use
JPS5813541A (ja) * 1981-07-16 1983-01-26 Kureha Chem Ind Co Ltd エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
US4424209A (en) * 1982-06-21 1984-01-03 Key Pharmaceuticals, Inc. 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes
JPS5910510A (ja) * 1982-07-08 1984-01-20 Nippon Zenyaku Kogyo Kk 低刺激性チアムリン注射剤
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
HU190818B (en) * 1982-11-09 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing complexes of piperonyl-butoxide-cyclodextrin
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
US4751095A (en) * 1983-07-28 1988-06-14 Karl Curtis L Aspartame stabilization with cyclodextrin
JPS6081166A (ja) * 1983-10-11 1985-05-09 Fujisawa Pharmaceut Co Ltd ２−ニトロオキシメチル−６−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US4675395A (en) * 1984-03-14 1987-06-23 Seiwa Technological Laboratories Limited Cyclodextrin inclusion compound and process for its preparation
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS61207380A (ja) * 1985-03-11 1986-09-13 Taiyo Yakuhin Kogyo Kk モベンゾキサミンの経口製剤
JPS61286318A (ja) * 1985-06-13 1986-12-16 Ichiro Shibauchi 浴剤の製造方法
US4663316A (en) * 1985-06-28 1987-05-05 Warner-Lambert Company Antibiotic clathrates and pharmaceutical compositions thereof
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
US4623641A (en) * 1985-09-09 1986-11-18 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
JP3176716B2 (ja) * 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
EP0519428B1 (en) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Cyclodextrin compositions with fumagillol derivates
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途

Also Published As

Publication number Publication date
DK0717638T3 (da) 2002-07-01
US20020058634A1 (en) 2002-05-16
DE69430126D1 (de) 2002-04-18
EP0717638A1 (en) 1996-06-26
AU7718694A (en) 1995-03-22
IL110825A0 (en) 1995-05-26
CA2172159A1 (en) 1995-03-09
US5602112A (en) 1997-02-11
US5804568A (en) 1998-09-08
US6048845A (en) 2000-04-11
US6583125B2 (en) 2003-06-24
WO1995006485A1 (en) 1995-03-09
US6284747B1 (en) 2001-09-04
HU9600612D0 (en) 1996-05-28
DE69430126T2 (de) 2002-08-01
ES2171462T3 (es) 2002-09-16
EP0717638B1 (en) 2002-03-13
ATE214290T1 (de) 2002-03-15
US6218374B1 (en) 2001-04-17
HUT73778A (en) 1996-09-30
JPH09502185A (ja) 1997-03-04
CA2172159C (en) 2003-07-29

Similar Documents

Publication Publication Date Title
PT717638E (pt) Ciclodextrinas para a reducao da toxicidade por extravasao provocada por substancias citotoxicas
AU773506B2 (en) Antitumour synergistic composition
FR2708608B1 (fr) Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
GEP19991649B (en) Composition of Derivatives of Cyclodextrins, Clathrating Composition Comprising the Same and Pharmaceutical Composition.
DE69918819T2 (de) Antikrebs-zusammensetzung enthaltend eine synergistische kombination bestehend aus einem anthracyclin-derivat mit einen camptothecin-derivat
CZ289570B6 (cs) Farmaceutické formulace obsahující vorikonazol
ATE238053T1 (de) Formulierungen und zusammensetzungen von in wasser schwer löslichen camptothecinderivaten
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
ES2118834T3 (es) Sistema mejorado de penetracion en la piel para la administracion topica mejorada de farmacos.
CA2292359A1 (en) Novel azalides and methods of making same
KR950702994A (ko) 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol)
YU11699A (sh) 6-supstituisani ketolidi koji imaju antibakterijsko dejstvo, postupci za njihovo dobijanje i njihovi farmaceutski preparati
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
WO2000044761A3 (en) Ketolide antibiotics
KR987000322A (ko) 신규 안트라시클린 화합물 유도체 및 이를 함유하는 의약 제제(novel anthracycline compound derivative and pharmaceutical preparation containing the same)
AU678344B2 (en) Lipophilic oligosaccharide antibiotic salt compositions
BR0212036A (pt) Composições farmacêuticas compreendendo conjugados de polissacarìdeos para a inibição da metástase ou prevenção da recorrência de tumor maligno
DK0422497T3 (da) Inklusionskomplekser med Silybinin, deres fremstilling af farmaceutiske præparater, der indeholder dem
WO1996023771A3 (en) Platelet aggregation inhibitors
WO1999057125A3 (en) Hygromycin a derivatives
AU5284999A (en) New injectable formulations containing ramoplanin
WO2003030884A2 (en) Use of solasonine for the treatment of skin tumors
WO2003030915A1 (en) Use of solamargine for treating skin tumors
RU92016472A (ru) Противовирусные средства, содержащие гетерополимолибдаты, способ лечения или профилактики инфекций, связанных с ретровирусом, применение гетерополимолибдатов для получения лекарственных средств, гетерополимолибдаты